| Cite this article: |
| YUE Siyu,QI Xiao,LIANG Guodong,GA Lu,GAO Xin,BU Ren,ZHAO Dongming,MA Yuheng,LIU Bin.The R&D strategy analysis for Mongolian medicines under the new Chinese medicine registration policy[J].Journal Of Pharmaceutical Research,2026,45(1):47-54[Click to copy] |
|
| This article has been viewed: 2836times Download 791次 |
 Scan with your phone! |
| 中药注册新政背景下蒙药新药开发策略 |
| 岳思雨1,2,齐晓1,梁国栋1,3,嘎鲁1,高鑫1,布仁1,赵东敏1,马宇衡1,刘斌2 |
|
|
| (1.内蒙古医科大学药学院,基于化学生物学的候选药物设计与筛选重点实验室,内蒙古 呼和浩特 010110;2.内蒙古大唐药业股份有限公司,内蒙古国际蒙医药研究院,内蒙古 呼和浩特 011599;3.臻相技术有限责任公司,内蒙古 呼和浩特 011517) |
|
| 摘要: |
| 本文探讨在中药注册新政策背景下蒙药发展的机遇与挑战,并提出现代化发展路径。分析蒙药创新药研发中网络药理学技术的应用,以及“计算-实验-临床”一体化模式的构建;讨论新药材开发与生态保护的平衡问题;阐述经典名方开发的政策支持与质量标准建立;指出同名同方药需借鉴中药经验避免低水平重复。研究认为,蒙药新药开发应以政策为导向,充分把握经典名方注册、改良型新药研发等机遇,坚持传承与创新并重,通过多学科技术融合与全产业链协同,实现现代化与国际化发展目标。 |
| 关键词: 中药注册 蒙药创新药 蒙药改良型新药 蒙药古代经典名方 同名同方蒙药 现代化开发 |
| DOI:10.13506/j.cnki.jpr.2026.01.008 |
| 基金项目:呼和浩特市科技“突围”工程重点示范项目—“揭榜挂帅”重大科技项目(No.2024-揭榜挂帅-社-2) |
|
Publication Date:January 26, 2026
|
|
| The R&D strategy analysis for Mongolian medicines under the new Chinese medicine registration policy |
| YUE Siyu1,2,QI Xiao1,LIANG Guodong1,3,GA Lu1,GAO Xin1,BU Ren1,ZHAO Dongming1,MA Yuheng1,LIU Bin2 |
| (1.Key Laboratory for Candidate medicine Design and Screening Based on Chemical Biology, College of Pharmacy, Inner Mongolia Medical University, Hohhot 010110, China; 2.Inner Mongolia International Mongolian Medicine Research Institute, Inner Mongolia Grand Pharmaceutical Co., Ltd., Hohhot 011599, China; 3.Zhen-Xiang Technology Co., Ltd., Hohhot 011517, China) |
| Abstract: |
| This manuscript aims to discuss the opportunities and the development challenges of Mongolian medicines under the background of the new policies for traditional Chinese medicine registration and proposes the path of modernization and development. It analyzes the application of network pharmacology and other technologies in the research and development (R&D) of innovative Mongolian medicines and the construction of the “computation-experimentation-clinical” holistic model. It discusses the balance between developing new Mongolian herbs and protecting the environment. It elaborates on policy support for developing classic prescriptions and establishing quality standards. It points out that Mongolian medicines with the same name need to draw on Chinese medicine's experience to avoid low-level duplication. The new Mongolian medicines R&D should be guided by policies. It should fully seize opportunities such as the registration of classic formulas and the development of improved new drugs, and adhere to the equal importance of inheritance and innovation. Ultimately, achieve the sustainable development goals of modernization and internationalization through the in-depth integration of multidisciplinary technologies and the efficient synergy of the whole industrial chain. |
| Key words: Chinese medicine registration Mongolian innovative medicines Mongolian modified medicines Mongolian medicine classical prescriptions Mongolian medicines with same name and formula Modernization development |